Effect of Bacille Calmette–Guérin vaccination on immune responses to SARS-CoV-2 and COVID-19 vaccination

Nicole L. Messina, Susie Germano, Amy W. Chung, Carolien E. van de Sandt, Natalie E. Stevens, Lilith F. Allen, Rhian Bonnici, Julio Croda, Claudio Counoupas, Branka Grubor-Bauk, Ebene R. Haycroft, Katherine Kedzierska, Ellie McDonald, Rebecca McElroy, Mihai G. Netea, Boris Novakovic, Kirsten Perrett, Laure F. Pittet, Ruth A. Purcell, Kanta SubbaraoJames A. Triccas, David J. Lynn, Nigel Curtis, the BRACE Trial Consortium Group, Stephen Blake, Miriam Lynn, Steve Wesselingh

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)
35 Downloads (Pure)

Abstract

Objectives: Bacille Calmette–Guérin (BCG) vaccination has off-target effects on disease risk for unrelated infections and immune responses to vaccines. This study aimed to determine the immunomodulatory effects of BCG vaccination on immune responses to vaccines against SARS-CoV-2. 

Methods: Blood samples, from a subset of 275 SARS-CoV-2-naïve healthcare workers randomised to BCG vaccination (BCG group) or no BCG vaccination (Control group) in the BRACE trial, were collected before and 28 days after the primary course (two doses) of ChAdOx1-S (Oxford-AstraZeneca) or BNT162b2 (Pfizer-BioNTech) vaccination. SARS-CoV-2-specific antibodies were measured using ELISA and multiplex bead array, whole blood cytokine responses to γ-irradiated SARS-CoV-2 (iSARS) stimulation were measured by multiplex bead array, and SARS-CoV-2-specific T-cell responses were measured by activation-induced marker and intracellular cytokine staining assays. 

Results: After randomisation (mean 11 months) but prior to COVID-19 vaccination, the BCG group had lower cytokine responses to iSARS stimulation than the Control group. After two doses of ChAdOx1-S, differences in iSARS-induced cytokine responses between the BCG group and Control group were found for three cytokines (CTACK, TRAIL and VEGF). No differences were found between the groups after BNT162b2 vaccination. There were also no differences between the BCG and Control groups in COVID-19 vaccine-induced antigen-specific antibody responses, T-cell activation or T-cell cytokine production. 

Conclusion: BCG vaccination induced a broad and persistent reduction in ex vivo cytokine responses to SARS-CoV-2. Following COVID-19 vaccination, this effect was abrogated, and BCG vaccination did not influence adaptive immune responses to COVID-19 vaccine antigens.

Original languageEnglish
Article numbere70023
Number of pages18
JournalClinical and Translational Immunology
Volume14
Issue number1
DOIs
Publication statusPublished - 25 Jan 2025

Keywords

  • Bacille Calmette–Guérin (BCG) vaccine
  • COVID-19
  • heterologous
  • immunity
  • immunomodulation

Fingerprint

Dive into the research topics of 'Effect of Bacille Calmette–Guérin vaccination on immune responses to SARS-CoV-2 and COVID-19 vaccination'. Together they form a unique fingerprint.

Cite this